Pharmacological therapy of portal hypertension--focused on Korean data

Research output: Contribution to journalArticle

Abstract

Portal hypertension as a consequence of liver cirrhosis is responsible for serious complications such as variceal bleeding, ascites and hepatic encephalopathy. Successful pharmacological treatment of portal hypertension can prevent the risk of the variceal bleeding, and contribute to reduce the morbidity and mortality in patients with liver cirrhosis. To identify the effect of drugs on portal hypertension, portal pressure was evaluated accurately before and after the drug administration. The hepatic venous pressure gradient has been accepted as the gold-standard method for assessing the severity of portal hypertension and the response to drug treatment. The mean hepatic venous pressure gradient was 15.1+/-5.4 mmHg in Korean cirrhotic patients who had experienced variceal bleeding. Non-selective beta blockers are the treatment of choice for primary and secondary prevention of variceal bleeding. The dose of propranolol should be subsequently adjusted until the resting heart rate had been reduced by 25% or less than 55 beats per minute. It has been reported that the optimal dose of propranolol is variable due to racial differences in cardiovascular receptor sensitivity. In Korean patients with portal hypertension and liver cirrhosis, the mean required dose of propranolol to reach target heart rate was 165 mg (range; 80-280 mg). This review covers mainly the results of the pharmacological therapy of portal hypertension in Korean cirrhotic patients.

Original languageEnglish
Pages (from-to)381-386
Number of pages6
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume45
Issue number6
Publication statusPublished - 2005 Jan 1

Fingerprint

Portal Hypertension
Pharmacology
Propranolol
Liver Cirrhosis
Hemorrhage
Venous Pressure
Therapeutics
Heart Rate
Pharmaceutical Preparations
Portal Pressure
Hepatic Encephalopathy
Liver
Primary Prevention
Secondary Prevention
Ascites
Gold
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{fbc21d784876404eac06930fc8d1eaf2,
title = "Pharmacological therapy of portal hypertension--focused on Korean data",
abstract = "Portal hypertension as a consequence of liver cirrhosis is responsible for serious complications such as variceal bleeding, ascites and hepatic encephalopathy. Successful pharmacological treatment of portal hypertension can prevent the risk of the variceal bleeding, and contribute to reduce the morbidity and mortality in patients with liver cirrhosis. To identify the effect of drugs on portal hypertension, portal pressure was evaluated accurately before and after the drug administration. The hepatic venous pressure gradient has been accepted as the gold-standard method for assessing the severity of portal hypertension and the response to drug treatment. The mean hepatic venous pressure gradient was 15.1+/-5.4 mmHg in Korean cirrhotic patients who had experienced variceal bleeding. Non-selective beta blockers are the treatment of choice for primary and secondary prevention of variceal bleeding. The dose of propranolol should be subsequently adjusted until the resting heart rate had been reduced by 25{\%} or less than 55 beats per minute. It has been reported that the optimal dose of propranolol is variable due to racial differences in cardiovascular receptor sensitivity. In Korean patients with portal hypertension and liver cirrhosis, the mean required dose of propranolol to reach target heart rate was 165 mg (range; 80-280 mg). This review covers mainly the results of the pharmacological therapy of portal hypertension in Korean cirrhotic patients.",
author = "Soonkoo Baik",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "45",
pages = "381--386",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "6",

}

Pharmacological therapy of portal hypertension--focused on Korean data. / Baik, Soonkoo.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 45, No. 6, 01.01.2005, p. 381-386.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacological therapy of portal hypertension--focused on Korean data

AU - Baik, Soonkoo

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Portal hypertension as a consequence of liver cirrhosis is responsible for serious complications such as variceal bleeding, ascites and hepatic encephalopathy. Successful pharmacological treatment of portal hypertension can prevent the risk of the variceal bleeding, and contribute to reduce the morbidity and mortality in patients with liver cirrhosis. To identify the effect of drugs on portal hypertension, portal pressure was evaluated accurately before and after the drug administration. The hepatic venous pressure gradient has been accepted as the gold-standard method for assessing the severity of portal hypertension and the response to drug treatment. The mean hepatic venous pressure gradient was 15.1+/-5.4 mmHg in Korean cirrhotic patients who had experienced variceal bleeding. Non-selective beta blockers are the treatment of choice for primary and secondary prevention of variceal bleeding. The dose of propranolol should be subsequently adjusted until the resting heart rate had been reduced by 25% or less than 55 beats per minute. It has been reported that the optimal dose of propranolol is variable due to racial differences in cardiovascular receptor sensitivity. In Korean patients with portal hypertension and liver cirrhosis, the mean required dose of propranolol to reach target heart rate was 165 mg (range; 80-280 mg). This review covers mainly the results of the pharmacological therapy of portal hypertension in Korean cirrhotic patients.

AB - Portal hypertension as a consequence of liver cirrhosis is responsible for serious complications such as variceal bleeding, ascites and hepatic encephalopathy. Successful pharmacological treatment of portal hypertension can prevent the risk of the variceal bleeding, and contribute to reduce the morbidity and mortality in patients with liver cirrhosis. To identify the effect of drugs on portal hypertension, portal pressure was evaluated accurately before and after the drug administration. The hepatic venous pressure gradient has been accepted as the gold-standard method for assessing the severity of portal hypertension and the response to drug treatment. The mean hepatic venous pressure gradient was 15.1+/-5.4 mmHg in Korean cirrhotic patients who had experienced variceal bleeding. Non-selective beta blockers are the treatment of choice for primary and secondary prevention of variceal bleeding. The dose of propranolol should be subsequently adjusted until the resting heart rate had been reduced by 25% or less than 55 beats per minute. It has been reported that the optimal dose of propranolol is variable due to racial differences in cardiovascular receptor sensitivity. In Korean patients with portal hypertension and liver cirrhosis, the mean required dose of propranolol to reach target heart rate was 165 mg (range; 80-280 mg). This review covers mainly the results of the pharmacological therapy of portal hypertension in Korean cirrhotic patients.

UR - http://www.scopus.com/inward/record.url?scp=33748750711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748750711&partnerID=8YFLogxK

M3 - Article

C2 - 15973071

AN - SCOPUS:33748750711

VL - 45

SP - 381

EP - 386

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 6

ER -